Review
Copyright ©The Author(s) 2016.
World J Gastroenterol. Sep 7, 2016; 22(33): 7463-7477
Published online Sep 7, 2016. doi: 10.3748/wjg.v22.i33.7463
Table 1 Review of the biological effects of bile acids
Ref.YearCell/tissueBile acidDoseTimeBiological effect
Jean-Louis et al[90]2006HCT 116DCA500 μmol/L5, 15, 30 minCholesterol aggregation at membrane
1, 2, 4 h
DCA500 μmol/L1 hInternalization of caveolin-1
Hirano et al[92]1991Gastric mucosal primary cultureDCA30 minPKC activation
DeRubertis et al[93]1987Colonic epithelial cellsDCADAG ↑
Takano et al[94]1984Colonic epithelial cellsDCA2 dDNA ↑
ODC ↑
Magnuson et al[95]1994In vivoCA2% in diet18 wkApoptosis ↓
Garewal et al[96]1996BiopsiesDCA1 mmol/L30 °C 3 hApoptosis ↓
Tucker et al[97]2004BxPC3CDCA, DCA100 μmol/L6-12 hCOX-2 ↑
SU86.86PGE-2 ↑
Glinghammar et al[98]2001HCT 116Tauro-CDCA200-1200 μmol/L15 hAP-1 ↑, COX-2 ↑, PKC(+), P38(+)
DCA, CDCA, CA250 μmol/L
Butyric acid0.1-4 mmol/L
HT 29DCA500 μmol/L24 hCOX-2 ↑, PCNA ↑
Raufman et al[100]2015In vivo (Asbt-deficient)Aberrant crypt foci
Cheng et al[101]2007H508DCT50 μmol/L24 hMMP ↑
Kitamura et al[104]2015Primary culture (BK5 erbB2 mice)TCDC100 μmol/L72 hCell proliferation ↑, EGFR MAPK Cyclin D1 ↑
Sk-Ch-A-1TCDC10-200 μmol/L72 hCell viability ↑
CDCA, DCA, TC, TDC0.5 mmol/L30 minp-erbB2, p-EGFR, p-MAPK, p-Akt ↑
TCDC500 μmol/L3 hHB-EGF ↑
TCDC200 μmol/L60 minTACE activity ↑
In vivo (BK5 erbB2 mice)TCDC2.5 mmol/L 200 μLTwice/wk for 20 wkSkin tumor ↑
Qiao et al[105]2001hepatocytesDCA50 μmol/L5 minEGFR/Ras/MAPK activation
Rao et al[106]2002Primary rat hepatocytesTDCA, TCA, DCA50 μmol/L20 minp-raf-1↑, MEK ↑, ERK ↑
Nagathihalli et al[5]2014HCT116, HCA-7, BxPC3, AsPC-1, Capan 2DCA300 μmol/L4 h-6 hTACE co-localization, TGF-α mRNA ↑